Comparable Overseas Reports (COR-A) pathway - First registration decision
Cabozantinib (CABOMETYX) is the first medicine to be registered via the new COR-A pathway
Published
Related content
-
Provisional approval pathway: prescription medicines
Information to help sponsors understand the provisional approval pathway for prescription medicines. -
Lapse of provisional registration for Tecentriq (atezolizumab) for the treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)
Provisional registration of Tecentriq (atezolizumab) for the treatment in mTNBC will lapse on 22 March 2023. -
MMDR: Complementary medicine regulatory reforms
The complementary medicine regulatory reforms include changes that will create a new approval pathway for listed complementary medicines and increase availability of information to support consumer decisions.